Pfizer Inc. $PFE Stock: Parcion Private Wealth LLC Grows Holdings

Parcion Private Wealth LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 145.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 51,586 shares of the biopharmaceutical company’s stock after purchasing an additional 30,549 shares during the period. Parcion Private Wealth LLC’s holdings in Pfizer were worth $1,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in PFE. BlackRock Inc. lifted its holdings in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. State Street Corp boosted its position in shares of Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Pfizer by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after purchasing an additional 3,999,646 shares during the period. Bank of America Corp DE purchased a new position in Pfizer during the 2nd quarter worth approximately $1,049,602,000. Finally, Dimensional Fund Advisors LP grew its stake in Pfizer by 0.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after buying an additional 293,029 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $30.48 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $30.67. The firm has a 50-day simple moving average of $28.55 and a 200-day simple moving average of $26.79. The company has a market capitalization of $173.73 billion, a price-to-earnings ratio of 40.11, a price-to-earnings-growth ratio of 2.07 and a beta of 0.32.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. HSBC lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Cantor Fitzgerald raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 9th. Finally, Scotiabank lifted their target price on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. Five investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.65.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.